Reading view
A Survey of Agentic AI and Cybersecurity: Challenges, Opportunities and Use-case Prototypes
Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making
Cancers (Basel). 2025 Dec 27;18(1):94. doi: 10.3390/cancers18010094.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor long-term survival despite advances in surgical techniques, systemic therapies, and perioperative management. High rates of systemic recurrence following curative-intent resection suggest that many patients harbor minimal residual disease (MRD), microscopic tumor burden that persists postoperatively and remains undetectable by conventional diagnostic tools. Recent advances in liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, alongside detailed characterization of the PDAC mutational landscape, offer a promising non-invasive approach for MRD detection. Emerging evidence indicates that MRD status can serve as a sensitive prognostic biomarker, identify patients at high risk of relapse, and guide personalized perioperative therapy, including optimization of adjuvant treatment. This review summarizes current knowledge on the biology and detection of MRD in PDAC, its implications for perioperative risk stratification and treatment decision-making, and discusses future directions for integrating MRD assessment into clinical practice to enable more precise, individualized patient management.
PMID:41514607 | PMC:PMC12784771 | DOI:10.3390/cancers18010094
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y
In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.Sci-Reasoning: A Dataset Decoding AI Innovation Patterns
Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search
Balancing Usability and Compliance in AI Smart Devices: A Privacy-by-Design Audit of Google Home, Alexa, and Siri
Fast Mining and Dynamic Time-to-Event Prediction over Multi-sensor Data Streams
Smart IoT-Based Wearable Device for Detection and Monitoring of Common Cow Diseases Using a Novel Machine Learning Technique
Atlas 2 -- Foundation models for clinical deployment
A Framework for Responsible AI Systems: Building Societal Trust through Domain Definition, Trustworthy AI Design, Auditability, Accountability, and Governance
SciClaims: An End-to-End Generative System for Biomedical Claim Analysis
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
STAT+: OpenAI invites you to upload medical records to ChatGPT
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Millions of people, including me and possibly you, are already asking ChatGPT questions about health. Still others are dumping otherwise inscrutable medical records downloaded from patient portals into the generative AI bot, hoping to glean new insights.
Now, OpenAI will encourage this behavior with a new health specific tab in the service that the company says has better security and privacy protections so users feel safe pouring sensitive medical data into the bot. In addition to uploading files, users can hook up data from products like Apple Health and Weight Watchers or obtain medical records from providers through b.well’s network. OpenAI promises that it won’t train its models on the data you put into ChatGPT Health. (Reminder: Data that you upload to a consumer service is not covered by HIPAA.)
Continue to STAT+ to read the full story…


© Adobe